| Literature DB >> 25660334 |
Xianxie Zhang1, Zengchun Ma1, Qiande Liang1, Xianglin Tang1, Donghua Hu1, Canglong Liu1, Hongling Tan1, Chengrong Xiao1, Boli Zhang2, Yuguang Wang3, Yue Gao4.
Abstract
Tanshinone IIA (Tan IIA) is one of the main natural active ingredients purified from Salvia miltiorrhiza radix, which has long been used in clinical practice in China to treat diseases including liver fibrosis, Alzheimer׳s disease, and cardiovascular diseases. Tan IIA has hepatoprotective properties, and is an efficacious PXR agonist. Our study was designed to observe the function and mechanism of the hepatoprotective properties of Tan IIA. HepG2 cells were used to investigate the vitrol effects of Tan IIA on PXR and CYP3A4. Gut-formed LCA is hepatotoxic, and has been implicated in the pathogenesis of cholestatic diseases. To further investigate the hepatoprotective mechanisms of Tan IIA against LCA-induced cholestasis in vivo, we choose the normal mice and siRNA-treated mice. The in vitro study demonstrated that the effect of Tan IIA on CYP3A4 was mediated by transactivation of PXR in a dose- and time-dependent manner. The in vivo experiments using PXR siRNA revealed that Tan IIA could protect against LCA-induced hepatotoxicity and cholestasis in a dose-dependent manner. These effects were partially caused by the upregulation of PXR, as well as Cyp3a11, Cyp3a13, and Mdr1, which are the enzymes responsible for LCA metabolism. This is the first report showing that the hepatoprotective effects of Tan IIA are partly mediated by PXR.Entities:
Keywords: Hepatotoxicity and cholestasis; Lithocholic acid (PubChem CID: 434-13-9); Pregnane X receptor; Tanshinone IIA (PubChem CID: 568-72-9);
Mesh：
Substances：
Year: 2015 PMID： 25660334 DOI： 10.1016/j.jep.2015.01.047
Source DB: PubMed Journal: J Ethnopharmacol ISSN： 0378-8741 Impact factor: 4.360